CME Symposium-Tailoring LDL-C-Lowering Therapy to Patient Cardiovascular Risk: Identifying Effective Strategies for Patients with Diabetes

This CME Symposium takes place on Sunday, June 9, 2019, from 6:45 PM- 9:15 PM at the San Francisco Marriott Marquis, Yerba Buena 9-15, San Francisco, California.
 
2019 ADA Invitation 21911
2019 ADA Invitation 21911
SPRINGFIELD, N.J. - May 16, 2019 - PRLog -- Register online now

Reducing LDL-C is a fundamentally important, guideline recommended strategy in the management of patients with diabetes. Although most adults 40-75 years of age with diabetes are at intermediate risk or high risk of their first atherosclerotic cardiovascular disease (ASCVD) event, evaluation of ASCVD risk will help refine risk estimates and therapeutic decision-making. In the 2018 multi-society cholesterol guidelines approved by the ADA, nonstatin therapy is recommended for consideration in patients with diabetes at heightened risk for ASCVD but without clinical ASCVD. Furthermore, diabetes is considered in these guidelines to be a high-risk condition; nonstatin therapy is recommended for secondary prevention in patients with very high-risk ASCVD and high-risk conditions. Ezetimibe and PCSK9 inhibitors  re nonstatin therapies that reduce LDL-C in high-risk patients. These drugs have been evaluated in cardiovascular outcomes trials (CVOTs), and analyses from these trials have been presented and published in patients with diabetes. In this program, a panel of experts will discuss the latest guidelines for managing LDL-C in patients with diabetes, interpret data with nonstatin, LDL-C-lowering therapies, describe improving access to PCSK9 inhibitors and tips for achieving earlier access, and utilize case presentations to demonstrate best practices for incorporating nonstatin therapy to reduce LDL-C and cardiovascular risk in patients with diabetes.

Register online now

Chair:
James Underberg, MD, MS
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, New York

Faculty:
Ty Gluckman, MD
Medical Director, Center for Cardiovascular
Analytics, Research, and Data Science
Providence Heart Institute
Providence St. Joseph Health
Portland, Oregon

Michael Shapiro, DO
Associate Professor of Medicine and Radiology
Oregon Health & Science University
Portland, Oregon

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Voxmedia International gratefully acknowledges the educational donation provided by Amgen.

This educational activity is intended for endocrinologists/diabetologists attending the American Diabetes Association's 79th Scientific Sessions.

Pre-registration is for planning purposes only.

For additional CME activities and online cme courses visit CMEPlanet

End
Source:Voxmedia LLC
Email:***@voxmedia.us Email Verified
Tags:Ada, Continuing Medical Education, Diabetes, Cme, LDL-C
Industry:Education, Event, Medical
Location:Springfield - New Jersey - United States
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share